25I Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EDT
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.22
Previous CloseN/A
Volume0.00
Average Volume (3M)69.00
Market Cap
€26.10M
Enterprise Value€18.98M
Total Cash (Recent Filing)€1.35M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta6.49
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume0
30 Day Avg. Volume69
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtNear-zero reported debt reduces near-term leverage risk and preserves financial optionality. For a clinical-stage biotech that needs periodic financing, low debt lowers bankruptcy risk and makes equity or partnership funding less encumbered, a durable strength for runway management.
Narrowing Net LossesA consistent reduction in annual losses indicates the company has been cutting costs or improving operating efficiency. Narrowing losses extend runway and lower near-term financing needs, signaling operational progress that could be sustained over the next several quarters if trends continue.
Improving Free Cash Flow TrendAn improving free cash flow trend demonstrates progress toward cash efficiency and reduced cash consumption. While still negative, improving FCF reduces reliance on external funding over time and reflects lasting gains in cost control or milestone-driven inflows if continued.
Bears Say
No Recent RevenueThe absence of recurring product or licensing revenue leaves the company dependent on financing or partnerships to fund development. Without demonstrable commercial income, financing risk and execution risk remain elevated over the next 2–6 months as clinical progress must justify new funding.
Persistent Operating Cash BurnSustained negative operating cash flow (~-2.37M in 2025) indicates the business consumes cash to operate and will likely require additional capital. Persistent cash burn is a structural weakness that pressures the financing runway and can force dilutive raises or distressed funding if unaddressed.
Fragile Capital Structure / Equity VolatilityA history of negative equity reflects prior capital erosion and a thin balance sheet. Such volatility can complicate fundraising and partnership negotiations, increasing the cost and uncertainty of securing necessary development capital over the medium term.
ImmuPharma News
25I FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest stock price was <€0.01 and its highest was €0.22 in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is €26.10M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is Sep 24, 2026 which is in 49 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on May 27, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC does not currently pay dividends.
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 96.667%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in DE:25I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―